Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu klinické zkoušky kontrolované, časopisecké články, práce podpořená grantem
PubMed
17184146
DOI
10.33549/physiolres.931058
PII: 1058
Knihovny.cz E-zdroje
- MeSH
- adipokiny krev MeSH
- adiponektin krev MeSH
- časové faktory MeSH
- diabetes mellitus 2. typu krev komplikace farmakoterapie patofyziologie MeSH
- fenofibrát farmakologie terapeutické užití MeSH
- glykemický clamp MeSH
- glykovaný hemoglobin metabolismus MeSH
- HDL-cholesterol krev MeSH
- hypolipidemika farmakologie terapeutické užití MeSH
- index tělesné hmotnosti MeSH
- inzulinová rezistence * MeSH
- krevní glukóza účinky léků MeSH
- lidé MeSH
- obezita krev komplikace farmakoterapie patofyziologie MeSH
- PPAR gama agonisté MeSH
- resistin krev MeSH
- studie případů a kontrol MeSH
- triglyceridy krev MeSH
- tuková tkáň účinky léků metabolismus MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky kontrolované MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adipokiny MeSH
- adiponektin MeSH
- ADIPOQ protein, human MeSH Prohlížeč
- fenofibrát MeSH
- glykovaný hemoglobin MeSH
- HDL-cholesterol MeSH
- hypolipidemika MeSH
- krevní glukóza MeSH
- PPAR gama MeSH
- resistin MeSH
- RETN protein, human MeSH Prohlížeč
- triglyceridy MeSH
PPAR-alpha agonists improve insulin sensitivity in rodent models of obesity/insulin resistance, but their effects on insulin sensitivity in humans are less clear. We measured insulin sensitivity by hyperinsulinemic-isoglycemic clamp in 10 obese females with type 2 diabetes before and after three months of treatment with PPAR-alpha agonist fenofibrate and studied the possible role of the changes in endocrine function of adipose tissue in the metabolic effects of fenofibrate. At baseline, body mass index, serum glucose, triglycerides, glycated hemoglobin and atherogenic index were significantly elevated in obese women with type 2 diabetes, while serum HDL cholesterol and adiponectin concentrations were significantly lower than in the control group (n=10). No differences were found in serum resistin levels between obese and control group. Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration. Serum adiponectin or resistin concentrations were not significantly affected by fenofibrate treatment. All parameters of insulin sensitivity as measured by hyperinsulinemic-isoglycemic clamp were significantly lower in an obese diabetic group compared to the control group before treatment and were not affected by fenofibrate administration. We conclude that administration of PPAR-alpha agonist fenofibrate for three months did not significantly affect insulin sensitivity or resistin and adiponectin concentrations in obese subjects with type 2 diabetes mellitus. The lack of insulin-sensitizing effects of fenofibrate in humans relative to rodents could be due to a generally lower PPAR-alpha expression in human liver and muscle.
Citace poskytuje Crossref.org
